About: Nexsen Limited operates as a nanobiotechnology company that develops proprietary biosensing platforms for rapid, high-precision point-of-care (POC) medical diagnostics and point-of-use sensing for human health, food and animal health, and biosecurity applications. The company offers Group B Streptococcus (GBS) rapid sensor; StrepSure, a diagnostic for the detection of human GBS in expectant mothers; kidney diseases, a POC tests for the screening, detection, and ongoing monitoring of various subsets of acute kidney injury and chronic kidney disease; bovine mastitis, a farm diagnostic to detect mastitis early which helps farmers; biosecurity pathogen tests, a portable sensor for frontline detection of invasive pests and pathogens -built for customs officers, farmers, and quarantine zones. It also offers rapid diagnostic programs targeting traumatic brain injury and neonatal sepsis. In addition, it is involved in developing rapid dual sensors for the detection of E.coli and Salmonella. The company was incorporated in 2021 and is based in Sydney, Australia.
Sector: Healthcare
Industry: Biotechnology
Latest price: A$0.16 (-5.88%)
NXN ASX Nexsen Limited
Nexsen Limited share price
Atividade de preço de NXN
Último preço
$ 0,160
Variação (24h)
-0,01 AUD (5,88%)
Volume
144.39K
Volume (média 4 sem.)
-
Abertura
$ 0,17
Variação do dia
$ 0,16 - $ 0,17
Fechamento anterior
$ 0,17
Último negócio
30 Oct, 5:10 am GMT+0
Atrasado
30 Oct, 5:10 am GMT+0
NXN price performance
Atrasado
30 Oct, 5:10 am GMT+0
quote.marketSignals